- Oral presentation on SAR’579 / IPH6101, a potential
first-in-class NKp46/CD16-based NK cell engager targeting CD123;
SAR’579 / IPH6101 is ANKET® platform lead asset and under
development by partner Sanofi
- Two Trial in Progress posters including monalizumab in
non-small cell lung cancer, developed in collaboration with
AstraZeneca
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA)
(“Innate” or the “Company”) announced today three
abstracts including Innate’s product candidates have been accepted
for the American Society for Clinical Oncology (ASCO) 2023 Annual
Meeting, taking place June 2-6, 2023 in Chicago, IL.
One abstract for SAR’579, currently developed by Sanofi, has
been selected for oral presentation. SAR’579 is a potential
first-in-class NKp46/CD16-based NK cell engager targeting CD123
using Innate’s proprietary multi-specific antibody format
ANKET®.
Two abstracts with monalizumab in non-small cell lung cancer
clinical trials led by AstraZeneca have been accepted for trial in
progress posters.
ASCO abstract title details:
SAR’579 / IPH6101
Abstract: 7005 Abstract Title:
A first-in-human study of CD123 NK cell engager SAR443579 in
relapsed or refractory acute myeloid leukemia, B-cell acute
lymphoblastic leukemia, or high-risk myelodysplasia. Session
Type/Title: Oral Abstract Session - Hematologic Malignancies –
Leukemia, Myelodysplastic Syndromes, and Allotransplant Session
Date and Time: 6/2/2023, 1:00 PM - 4:00 PM
Monalizumab
Abstract: TPS8610 Poster Bd#
231b Abstract Title: Phase 3 study of durvalumab combined
with oleclumab or monalizumab in patients with unresectable stage
III NSCLC (PACIFIC-9). Session Type/Title: Poster Session –
Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other
Thoracic Cancers Session Date and Time: 6/4/2023, 8:00 AM
EDT
Abstract: TPS8604 Poster Bd#
228b Abstract Title: NeoCOAST-2: A phase 2 study of
neoadjuvant durvalumab plus novel immunotherapies (IO) and
chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by
surgery and adjuvant durvalumab plus novel IO or volrustomig alone
in patients with resectable non-small-cell lung cancer (NSCLC).
Session Type/Title: Poster Session – Lung Cancer - Non-Small
Cell Local-Regional/Small Cell/Other Thoracic Cancers Session
Date and Time: 6/4/2023, 8:00 AM EDT
According to ASCO Annual Meeting, full abstracts will become
public at 5:00 PM EDT on May 25, 2023. More details about the
programs for the ASCO Annual Meetings are available online at
www.asco.com
About ANKET®
ANKET® (Antibody-based NK cell Engager
Therapeutics) is Innate's proprietary platform for
developing next-generation, multi-specific natural killer (NK) cell
engagers to treat certain types of cancer.
This versatile, fit-for-purpose technology is creating an
entirely new class of molecules to induce synthetic immunity
against cancer.
About the Innate-Sanofi agreement:
The Company has a research collaboration and licensing agreement
with Sanofi to apply Innate’s proprietary technology to the
development of innovative multi-specific antibody formats engaging
NK cells through the activating receptors NKp46 and CD16 to kill
tumor cells.
Under the terms of the 2016 research collaboration and licensing
agreement, Sanofi is responsible for the development, manufacturing
and commercialization of products resulting from the research
collaboration, which includes IPH6101/SAR’579 (CD123 NK Cell
Engager) and IPH6401/SAR’514 (BCMA NK Cell Engager). Innate Pharma
will be eligible to up to €400m in development and commercial
milestone payments as well as royalties on net sales.
Under the terms of a new license agreement entered in December
2022, which includes IPH62 (B7-H3 NK Cell Engager) and 2 options,
Innate received €25m upfront payment and is eligible for up to
€1.35bn total in preclinical, clinical, regulatory and commercial
milestones plus royalties on potential net sales. Upon candidate
selection, Sanofi will be responsible for all development,
manufacturing and commercialization
About Monalizumab:
Monalizumab is a potentially first-in-class immune checkpoint
inhibitor targeting NKG2A receptors expressed on tumor infiltrating
cytotoxic CD8+ T cells and NK cells.
NKG2A is an inhibitory checkpoint receptor for HLA-E. By
expressing HLA-E, cancer cells can protect themselves from killing
by NKG2A+ immune cells. HLA-E is frequently overexpressed in the
cancer cells of many solid tumors and hematological malignancies.
Monalizumab may reestablish a broad anti-tumor response mediated by
NK and T cells, and may enhance the cytotoxic potential of other
therapeutic antibodies1.
AstraZeneca obtained full oncology rights to monalizumab in
October 2018 through a co-development and commercialization
agreement initiated in 2015. The ongoing development for
monalizumab is focused on investigating monalizumab in various
combination strategies in different malignancies.
About the Innate-AstraZeneca monalizumab agreement:
In October 2018, AstraZeneca obtained full oncology rights to
monalizumab by exercising its option under the co-development and
commercialization agreement initiated in 2015.
The financial terms of the agreement include potential cash
payments up to $1.275 billion to Innate Pharma. Including the $50
million payment triggered by dosing the first patient in the Phase
3 PACIFIC-9 clinical trial, Innate Pharma has received $450 million
to date.
For any commercialized oncology indication, AstraZeneca will
book all sales revenue and will pay Innate low double-digit to
mid-teen percentage royalties on net sales worldwide except in
Europe where Innate Pharma will receive 50% share of the profits
and losses in the territory. Innate will co-fund 30% of the costs
of the Phase 3 development program of monalizumab with a pre-agreed
limitation of Innate’s financial commitment.
About Innate Pharma
Innate Pharma S.A. is a global, clinical-stage biotechnology
company developing immunotherapies for cancer patients. Its
innovative approach aims to harness the innate immune system
through therapeutic antibodies and its ANKET®
(Antibody-based NK cell Engager
Therapeutics) proprietary platform.
Innate’s portfolio includes lead proprietary program lacutamab,
developed in advanced form of cutaneous T cell lymphomas and
peripheral T cell lymphomas, monalizumab developed with AstraZeneca
in non-small cell lung cancer, as well as ANKET® multi-specific NK
cell engagers to address multiple tumor types.
Innate Pharma is a trusted partner to biopharmaceutical
companies such as Sanofi and AstraZeneca, as well as leading
research institutions, to accelerate innovation, research and
development for the benefit of patients.
Headquartered in Marseille, France with a US office in
Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq
in the US.
Learn more about Innate Pharma at www.innate-pharma.com and
follow us on Twitter and LinkedIn.
______________________________
1 André et al, Cell 2018
Information about Innate Pharma shares
ISIN code
Ticker code
LEI
FR0010331421
Euronext: IPH Nasdaq: IPHA
9695002Y8420ZB8HJE29
Disclaimer on forward-looking information and risk
factors
This press release contains certain forward-looking statements,
including those within the meaning of the Private Securities
Litigation Reform Act of 1995. The use of certain words, including
“believe,” “potential,” “expect” and “will” and similar
expressions, is intended to identify forward-looking statements.
Although the company believes its expectations are based on
reasonable assumptions, these forward-looking statements are
subject to numerous risks and uncertainties, which could cause
actual results to differ materially from those anticipated. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including
related to safety, progression of and results from its ongoing and
planned clinical trials and preclinical studies, review and
approvals by regulatory authorities of its product candidates, the
Company’s commercialization efforts and the Company’s continued
ability to raise capital to fund its development. For an additional
discussion of risks and uncertainties which could cause the
company's actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque")
section of the Universal Registration Document filed with the
French Financial Markets Authority (“AMF”), which is available on
the AMF website http://www.amf-france.org or on Innate Pharma’s
website, and public filings and reports filed with the U.S.
Securities and Exchange Commission (“SEC”), including the Company’s
Annual Report on Form 20-F for the year ended December 31, 2022,
and subsequent filings and reports filed with the AMF or SEC, or
otherwise made public, by the Company.
This press release and the information contained herein do not
constitute an offer to sell or a solicitation of an offer to buy or
subscribe to shares in Innate Pharma in any country.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230502006194/en/
Investors Innate
Pharma Henry Wheeler Tel.: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr Media
Relations NewCap Arthur Rouillé Tel.: +33 (0)1 44
71 00 15 innate@newcap.eu
Innate Pharma (NASDAQ:IPHA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Innate Pharma (NASDAQ:IPHA)
Historical Stock Chart
From Apr 2023 to Apr 2024